As with HIV, Treatment as Prevention will be essential for elimination of hepatitis C

“Reaching people living with HIV with care, treatment and support to improve their longevity and quality of life, and to prevent new infections (a concept known as Treatment as Prevention®, or TasP® ) has helped bring the HIV epidemic under control in British Columbia. TasP® is a strategy many countries around the world have adopted. Now, the Canadian expert who developed TasP® is looking to transfer the success of this initiative to stamp out another global epidemic: hepatitis C.

Read the full story

Leave a Reply

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below